|Infinity Pharmaceuticals Inc -- USA Stock|| |
USD 2.1 0.6 22.22%
Vice President - Finance
Ms. Melissa Hackel serves as Vice President Finance of the Company. Melissa Hackel joined Infinity in 2015 and has more than 15 years of financial experience in the pharmaceutical and medical device industry and has made financial and operational contributions throughout her career leading and developing teams to manage financial analysis in support of strategic decisionmaking. Prior to joining Infinity, Ms. Hackel served as director of finance at Takeda Pharmaceutical Company. She received a MBA from Duke University and a B.A. in political science from Bates College.
President Since 2017 MBA
The company has return on total asset (ROA)
of (26.58) %
which means that it has lost $26.58 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE)
of (78.61) %
meaning that it created substantial loss on money invested by shareholders.
Infinity Pharmaceuticals, Inc., a drug discovery and development company, discovers, develops, and delivers medicines to patients with difficulttotreat diseases. Infinity Pharmaceuticals Inc (INFI) is traded on NASDAQ in USA. It is located in MASSACHUSETTS, U.S.A and employs 48 people. Infinity Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.